Yes, 2016 was a lousy year for many people and even for the drug industry, but for different reasons. I’ve already reviewed data from 2016 that document some good news for pharma (see “Charts & Graphs Tell the Story of Pharma in 2016“).
Another way to look at 2016 is through images. Some of my favorite images from 2016 are collected in the Slideshare presentation embedded below. Click on “Read more” to access a clickable list of references.
- “Judge, Jury and Executioner. Nice System.”
- The FDA-Pharma-FDA “Revolving Door”
- Opioid Epidemic Getting Worse Due to FDA, Which Now Says It Will Change Its Ways
- Will Califf, Nay, FDA Survive Under Trump?
- Pharma Pushes Back Against FDA’s Proposed Study of Animation in TV DTC Ads
- FDA to Study If Oldsters Understand TV Drug Ads
- TV DTC is Alive! But Ineffective!
- 50 Celebrities Who Shilled for Pharma. Et Tu, Wonder Woman?
- DTC Moratorium Idea Resurrected
- Consumers Miss Risk Info in DTC Ads, Says Eye-Tracking Study
- The Dark World of Disease Awareness Ads
- “Desperate Turds” Print Ad
- Pharma on Social Media Gets FDA’s Attention
- What’s Pharma Doing on Pinterest?
- Flowchart: How Pharma Can Handle Every Type of Comment on Social Media
- Pharma Must Digitize to be “Great Again”
- Digitally Savvy Women in Pharma
- Digital Health #FAIL!
- Consumers On Their Own When It Comes to Wearable Device & Data Security
- Patients Turn Up Heat on FDA
- 21st Century Cures for Pharmaceutical Marketing
- OMG! Drug Side Effects (Almost) Killed Granny!
- FDA Drops Black Box Warning on Chantix
- Anti-Vaccine Film Won’t be Screened at Tribeca Festival
- Teva to PhRMA: “Can’t We All Just Get Along?”
- When It Comes to Greed, Pharma & Insurers Are Two Sides of the Same Coin
- “1bn Here We Come!” A Common Goal for Pharma CEOs
- Valeant Fires, Then Rehires Xifaxan Sales Reps
- More Top Executives Flee Sinking Crooked Valeant Ship with $ Millions in Bonuses In Tow
- LA Times Columnist Not Drinking Kool- Aid Served Up by Saunders
- Oh Snap! Regeneron CEO Schleifer Said What to Pfizer CEO Read?
- Pharma Sis, Mylan CEO, Hits Her EpiPen Marketing Target: Moms! Price Gouging Followed
- J & J Guilty Again! Ordered to Pay $1 Billion in Putative Damages, the Largest This Year
- FDA May Soon Be Replaced by Judicial Off-Label Activism
- Pharma Sales Reps Would Be More “Helpful” If They Could Discuss Off-Label Drug Use
- Pharma Focuses on Payers as Likely Starting Point for Off-label Drug Promotion
- Patients with Chronic Conditions Are OK With Off- Label Drug Promotion
- Off-Label Direct-to-Consumer Promotion Survey
